Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events | Arteriosclerosis, Thrombosis, and Vascular Biology
Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy | Journal of Hematology & Oncology | Full Text
Immunological off-target effects of imatinib | Nature Reviews Clinical Oncology
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
Imatinib - an overview | ScienceDirect Topics
Journal of Biomedical and Pharmaceutical Research
Imatinib - Wikipedia
Imatinib Mesylate — A New Oral Targeted Therapy | NEJM
5MJCB4-TKI
What is Gleevec? - Quora
Mode of action of imatinib on BCR-ABL. ADP, adenosine diphosphate; ATP,... | Download Scientific Diagram
Imatinib | SpringerLink
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics | PLOS Computational Biology
Defining molecular mechanisms of imatinib treatment in GIST - The Life Raft Group
Journal of Biomedical and Pharmaceutical Research
EPOS™
Defining molecular mechanisms of imatinib treatment in GIST - The Life Raft Group
Frontiers | Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
File:Mechanism imatinib.svg - Wikimedia Commons
File:Mechanism imatinib.svg - Wikimedia Commons
Figure 1 from Quantification of an anti-cancer drug ( imatinib ) in human plasma | Semantic Scholar
Figure 2, Schematic model for the mechanism of action of Gleevec (imatinib) - Mechanistic Evidence in Evidence-Based Medicine: A Conceptual Framework - NCBI Bookshelf
Treatment of CML Transplant or Imatinib? Mark B Juckett MD Section of Hematology/BMT University of Wisconsin. - ppt download
Imatinib mechanism of action
